1

2

Disclaimer

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results. By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above. BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

3

BioSyent is a profitable, growth oriented Specialty

Pharmaceutical company that sources and markets innovative

products that improve the lives of patients and support the

healthcare professionals that treat them.

Today’s presentation by:

René C. Goehrum

Chairman, President & CEO of BioSyent Inc.

3

4

About BioSyent

Listed on the Toronto Venture Exchange, under the trading Symbol “RX,” U.S.

OTC “BIOYF”, BioSyent searches the globe to identify and acquire exclusive

rights to pharmaceutical products that have been successfully developed and

proven to be safe and effective. Once a product of interest has been found,

BioSyent then acquires the exclusive rights and manages these products

through the Canadian regulatory process (approval); and once approved,

markets these products throughout Canada.

Selected from over 2,200 listed companies, BioSyent was named as one of the

2012 TSX Venture Top 50 and was ranked #5 in the TSX Venture’s Life

Sciences and Technology group.

5

Investment Highlights

1. Proven business model with 2 marketed pharmaceutical

products; 1 product approved in preparation for 2013

launch; 2 products being prepared for Health Canada

filing.

2. High growth – during the period January 1, 2010

through September 30, 2012, revenue has grown at an

annualized compound growth rate of 69%.

3. Demonstrated profitability – 9 month 2012 basic EPS of

$0.08; FY2011 basic EPS $0.03; FY2010 basic EPS

$0.004.

4. No debt and an unutilized operating line of credit (Royal

Bank of Canada).

6

Investment Highlights

5. Strong Balance Sheet to fund continued growth – cash

and cash equivalents of $1.94 million as of September

30, 2012, representing YTD growth of 83% (+$0.88

million) over previous year-end.

6. Clean capital structure – 13,271,195 shares currently

issued and outstanding. No warrants outstanding.

1,205,000 options outstanding. Total diluted shares:

14,476,195.

7. Active in-licensing (new product) funnel.

8. Experienced management team.

7

Strategy

1. Expansion of our product base by in-licensing exclusive Canadian rights to

proven pharmaceutical products that address unmet medical needs.

2. Manage technology risk by focusing on already commercialized products,

not yet available in Canada.

3. Minimize deal competition by focusing on niche products with a peak

penetration potential of $2-15 million – below threshold of mid-size and

larger pharma companies.

4. BioSyent builds its sales and marketing teams around a product. This

approach maximizes profit and minimizes costs, as sales teams are put in

place only when needed and expand only when the product’s sales can

support the expansion.

8

Capabilities

1. Commercialization excellence in the 9th largest global

pharmaceutical market (IMS).

2. Regulatory Approval, QA-QC, Compliance.

3. Bilingual (English/French) operations, sales and customer service.

4. Canada-wide sales, marketing team.

5. Hospital, wholesaler and retail pharmacy distribution network.

6. Group hospital purchasing relationships (existing contracts).

7. All required drug licenses.

8. Medical/Drug information support.

9. Formulary and reimbursement management.

9

Sales Team

1. 10 medical sales representatives with an average of 20 years in

Pharma.

2. Broad experience base (Specialty, Hospital and GP) in a wide

variety of therapeutic classes.

3. Proximity to all major cities/population centers.

4. All markets including virtual territories supported by e-details, web,

direct mail, video conferencing, sampling programs.

5. We build teams to fit new product opportunities/needs.

10

Recent Corporate Events

Time Period Event

FY 2010 FY sales +63% , add 3 medical reps

July 2011 Health Canada approval of Cathejell ™

primary use in hospitals

FY 2011 FY sales +67%, add 3 medical reps

February 2012 BioSyent named to the TSX TOP 50 Ranking

Moved to new corporate head office

July 2012 Health Canada approval of FeraMAX® Powder.

1st new oral iron product for Canadian children in 50 years

August 2012 Sign exclusive licensing and distribution agreement

for 2 new drugs (patented)

September 2012 Sales team reaches 10 medical reps

September 2012 YTD September 30 sales reach $3.7 Million (+76%), Net Income grows 196%

Q1 2013 Planned FeraMAX® Powder product launch

Q1 2013 Planned 2 new products filed at Health Canada

11 11

12

Our Products | FeraMAX® 150

1. Approved by Health Canada for the

treatment of iron deficient anaemia

– therapeutic dose.

2. Distributed across Canada, broadly

available via ~ 8,000 pharmacies

including majors such as Shoppers

Drug Mart, Rexall, Jean Coutu, Wal-

Mart, Costco, Loblaw.

3. Clinically proven and effective. Well

tolerated, with an improved side-

effect profile.

4. Brand owned by BioSyent.

Exclusive supply deal.

12

13

Our Products | FeraMAX® Powder

1. Approved by Health Canada for

prevention of iron deficiency.

2. Extension of the FeraMAX® brand

– based upon the same

compound as FeraMAX® 150.

3. Developed in response to

requests by Paediatricians and

GPs that treat children.

4. Gentle on GI tract - reduced side

effects.

5. Pleasant taste improves

compliance.

14

Our Products | CATHEJELL™ Jelly 2%

1. Approved by Health Canada.

Proven safe and effective with 40

year track record in 54 countries.

2. Used as a Sterile Topical Anesthetic

- primarily in cystoscopies.

3. Unique collapsible accordion

syringe with trauma free applicator

tip.

4. Single handed application, no

syringe assembly required.

5. No restrictions of use in the

hospital.

14

15

COMPANY FINANCIAL INFORMATION

15

16

-

200,000

400,000

600,000

800,000

1,000,000

1,200,000

81,237

155,024 191,716

247,941

322,648

465,163

604,523 657,442

761,372

1,054,026

1,180,717

C$

Quarter

Pharmaceutical Products Sales By Quarter

16

17

$0

$500,000

$1,000,000

$1,500,000

$2,000,000

$2,500,000

$3,000,000

$3,500,000

$4,000,000

2008 2009 2010 2011 2012

$1,101,991 1,029,902

$1,681,210

$2,808,666

$3,696,201

CAD

Period

Revenue Growth 9 Months

(YTD Sept)

18

(400,000)

(200,000)

-

200,000

400,000

600,000

800,000

1,000,000

1,200,000

2008 2009 2010 2011 2012

(287,892) (260,556)

$48,386

$417,950

$1,034,828

CAD

Period

Total Comprehensive Income

9 Months

(YTD Sept)

19

(400,000)

(200,000)

-

200,000

400,000

600,000

800,000

1,000,000

2008 2009 2010 2011 2012

(295,260)

(351,725)

40,307

586,951

878,751

CAD

Period

Cash Flow9 Months

(YTD Sept)

19

20

Share Ownership by Management &

Directors

21 21

22

Management

René C. Goehrum | President & CEO

• 30+ years spanning start-up, early stage, growth and mature businesses;

• Prior operating and services experience: Procter & Gamble, Sandoz (now

Novartis), Boehringer Ingelheim and others;

• Functional experience: Leadership, strategy, business development,

operations, corporate finance, sales, marketing.

Alfred D'Souza | Vice-President & Chief Financial Officer

• Colgate Palmolive and Unilever in finance, accounting, mergers,

acquisitions. Last position before BioSyent - Finance Director Colgate

Palmolive India (USD $225 million). Start-up leadership team, Colgate

Vietnam, grew to $25 million.

23

Management

Kevin Wilson | Vice President of Sales and Marketing

• 20+ years experience in pharmaceutical sales, sales leadership, and

marketing at Abbott, Bayer, Pharmacia/Searle (now Pfizer);

• Director of Marketing on three different therapeutic classes.

Tom Carson | Director of Business Development

• 30+ years pharmaceutical experience in sales, product management,

marketing, sales information and business development;

• Prior experience: DuPont Pharma, Bristol Myers Squibb.

24

Directors

René C. Goehrum | Chairman Douglas R. Larson | Director Douglas Larson has considerable leadership and governance experience. Before August 1995, he served as President and CEO of James Richardson and Sons Ltd.- Grain Division, Canada’s largest privately owned grain company with sales in excess of $100 million and over 1200 employees. Peter Lockhard | Non-Executive Director Mr. Lockhard has extensive senior management experience with successful high-growth companies in the IT and marketing services industries, including VP Professional Services of Flo Network, a permission-based e-messaging service provider (acquired by DoubleClick). Mr. Lockhard currently serves as the Chief Operating Officer of Points International Ltd. a $125 million revenue company listed on Nasdaq and the TSX (Nasdaq:PCOM; TSX:PTS).

25

Directors

Milton E. Wakefield | Non-Executive Director Milton Wakefield completed a ten-year term as Commissioner of the Canadian Grain Commission, the last seven as its Chief Commissioner, in 1997. This organization had over 800 employees and an Operating Budget of $55 million. He also served eight years in the Legislative Assembly of the Province of Saskatchewan. Mr. Wakefield is currently the Chairman of the Board of Lakeland College in Alberta, an institution with over 8,000 students and an Operating Budget of over $65 million. Paul R. Montador | Non-Executive Director Mr. Montador has over 35 years of experience in healthcare product sales, marketing, leadership, and corporate governance. At present, he is the CEO (founder) of InspiAir Inc. and Chairman of the Board of ThinkFirst/Pensez d’Abord Canada, a national non-profit organization dedicated to the prevention of brain and spinal cord injuries. Mr. Montador’s roles have also included CEO of SciCan Inc., President of Johnson & Johnson Medical Products (Canada), President and Board member of Amsco Inc., General Manager of American Hospital Supply (Canada), and Board member of CryoCath Technologies Inc. (acquired by Medtronic Inc.).

26

Stock Information

February 5, 2013

Exchange & Trading Symbol: TSXV: RX

52 Week Hi / Low: $1.40 / $0.41

Current Shares: 13,271,195

Warrants: 0

Options: 1,205,000

Fully Diluted: 14,476,195

P/E Ratio: 13.80

P/B Ratio: 5.89

BioSyent has experienced strong stock performance over the last year with no

need to access debt or equity financing.

27

Contact Information

Investors: René Goehrum President and CEO (905) 206-0013 ext.320 rgoerhum@biosyent.com Business Development: Tom Carson Director of Business Development (905) 206-0013 ext.309 tcarson@biosyent.com Address: 170 Attwell Drive, Suite 520 Toronto, Ontario, Canada M9W 5Z5

28 28